Latest Articles

  • In Reply: Starting insulin therapy (August 2015)
    Andre Brateanu, MD, FACP, Giavanna Russo-Alvarez, PharmD, BCACP and Craig Nielsen, MD, FACP
    Cleveland Clinic Journal of Medicine October 2015, 82 (10) 638-639; DOI: https://doi.org/10.3949/ccjm.82c.10002

    Readers comment on resuming anticoagulation after hemorrhage (April 2015) and on starting insulin therapy in patients with type 2 diabetes (August 2015).

  • Lady Windermere syndrome: Mycobacterium of sophistication
    Christopher Donatelli, MD and Atul C. Mehta, MD, FACP, FCCP
    Cleveland Clinic Journal of Medicine October 2015, 82 (10) 641-643; DOI: https://doi.org/10.3949/ccjm.82a.14100

    The typical patient is a thin, well-mannered elderly woman who voluntarily suppresses her cough out of politeness.

  • A 56-year-old with diarrhea and weakness
    Marshall Edward McCabe, DO and Areeba Y. Kara, MD, MS, FACP
    Cleveland Clinic Journal of Medicine October 2015, 82 (10) 671-676; DOI: https://doi.org/10.3949/ccjm.82a.14124

    The patient has unintentionally lost 137 lb over the past year. What is the cause?

  • Reflux redux
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine October 2015, 82 (10) 633; DOI: https://doi.org/10.3949/ccjm.82b.10015

    Even the diseases we deal with every day sometimes warrant a second look.

  • Why do clinicians continue to order ‘routine preoperative tests’ despite the evidence?
    Andrei Brateanu, MD and Michael B. Rothberg, MD, MPH
    Cleveland Clinic Journal of Medicine October 2015, 82 (10) 667-670; DOI: https://doi.org/10.3949/ccjm.82a.15118

    The authors propose several reasons and possible solutions.

  • Sacubitril-valsartan and the evolution of heart failure care
    Randall C. Starling, MD, MPH, FACC, FESC
    Cleveland Clinic Journal of Medicine October 2015, 82 (10) 702-704; DOI: https://doi.org/10.3949/ccjm.82a.15121

    It was hard to believe that any new additional therapy would make a significant difference.

  • Resuming anticoagulation after hemorrhage (April 2015)
    Mohamad Badr Jandali, MD
    Cleveland Clinic Journal of Medicine October 2015, 82 (10) 639-640; DOI: https://doi.org/10.3949/ccjm.82c.10003

    Readers comment on resuming anticoagulation after hemorrhage (April 2015) and on starting insulin therapy in patients with type 2 diabetes (August 2015).

  • Genitourinary manifestations of sickle cell disease
    Surafel Gebreselassie, MD, Matthew N. Simmons, MD, PhD and Drogo K. Montague, MD
    Cleveland Clinic Journal of Medicine October 2015, 82 (10) 679-683; DOI: https://doi.org/10.3949/ccjm.82a.14029

    Sickling can lead to nephropathy, priapism, papillary necrosis, and renal medullary carcinoma.

  • Do healthy patients need routine laboratory testing before elective noncardiac surgery?
    Nathan Houchens, MD, FACP
    Cleveland Clinic Journal of Medicine October 2015, 82 (10) 664-666; DOI: https://doi.org/10.3949/ccjm.82a.14152

    Testing often increases costs and anxiety, with little benefit.

  • A new class of drugs for systolic heart failure: The PARADIGM-HF study
    A new class of drugs for systolic heart failure: The PARADIGM-HF study
    Marwa A. Sabe, MD, MPH, Miriam S. Jacob, MD and David O. Taylor, MD
    Cleveland Clinic Journal of Medicine October 2015, 82 (10) 693-701; DOI: https://doi.org/10.3949/ccjm.82a.14163

    Valsartan-sacubitril is the first new drug in over a decade to decrease death rates in patients with systolic heart failure.

Pages